ALIMTA Drug Patent Profile

When do Alimta patents expire, and when can generic versions of Alimta launch?

Alimta is a drug marketed by Lilly and is included in one NDA.

The generic ingredient in ALIMTA is pemetrexed disodium. There are twenty-nine drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the pemetrexed disodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Alimta

A generic version of ALIMTA was approved as pemetrexed disodium by ACCORD HLTHCARE on May 25^th, 2022.

Summary for ALIMTA

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	59
Clinical Trials:	345
Patent Applications:	4,865
Drug Prices:	Drug price information for ALIMTA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ALIMTA
What excipients (inactive ingredients) are in ALIMTA?	ALIMTA excipients list
DailyMed Link:	ALIMTA at DailyMed

See drug prices for ALIMTA

Recent Clinical Trials for ALIMTA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Saint John's Cancer Institute	PHASE2
Chordoma Foundation	PHASE2
Regeneron Pharmaceuticals	Phase 2

See all ALIMTA clinical trials

Pharmacology for ALIMTA

Drug Class	Folate Analog Metabolic Inhibitor
Mechanism of Action	Folic Acid Metabolism Inhibitors

Paragraph IV (Patent) Challenges for ALIMTA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ALIMTA	For Injection	pemetrexed disodium	750 mg/vial	021462	1	2016-10-06
ALIMTA	For Injection	pemetrexed disodium	1000 mg/vial	021462	1	2012-06-27
ALIMTA	For Injection	pemetrexed disodium	100 mg/vial	021462	1	2008-07-01
ALIMTA	For Injection	pemetrexed disodium	500 mg/vial	021462	2	2008-02-04

US Patents and Regulatory Information for ALIMTA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lilly	ALIMTA	pemetrexed disodium	POWDER;INTRAVENOUS	021462-002	Sep 7, 2007	AP	RX	Yes	Yes
Lilly	ALIMTA	pemetrexed disodium	POWDER;INTRAVENOUS	021462-001	Feb 4, 2004	AP	RX	Yes	Yes

Expired US Patents for ALIMTA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Lilly	ALIMTA	pemetrexed disodium	POWDER;INTRAVENOUS	021462-002	Sep 7, 2007
Lilly	ALIMTA	pemetrexed disodium	POWDER;INTRAVENOUS	021462-001	Feb 4, 2004
Lilly	ALIMTA	pemetrexed disodium	POWDER;INTRAVENOUS	021462-001	Feb 4, 2004

International Patents for ALIMTA

See the table below for patents covering ALIMTA around the world.

Country	Patent Number	Title	Estimated Expiration
Brazil	1101036
Russian Federation	2057131	ПРОИЗВОДНЫЕ N-(ПИРРОЛО[2,3-D]ПИРИМИДИН-3-ИЛАЦИЛ)-L-ГЛУТАМИНОВОЙ КИСЛОТЫ, ИЛИ ИХ ТАУМЕРЫ, ИЛИ ИХ ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМЫЕ СОЛИ И СПОСОБ ИХ ПОЛУЧЕНИЯ (DERIVATIVES OF N-(PYRROLO[2,3-D]PYRIMIDINE-3-YLACYL)-L-GLYTAMICE ACID OR THEIR TAUTOMERS, OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, AND METHOD FOR THEIR PREPARING)
Cyprus	1888	Improved therapeutic method

Supplementary Protection Certificates for ALIMTA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0432677	7/2005	Austria		PRODUCT NAME: PEMETREXED UND DESSEN PHARMAZEUTISCH ANNAHMBAREN SALZE; REGISTRATION NO/DATE: EU/1/04/290/001 20040920
0432677	CA 2005 00008	Denmark
0432677	300181	Netherlands		300181, 20101210, EXPIRES: 20151209

Market Dynamics and Financial Trajectory for ALIMTA (Pemetrexed)

Last updated: November 17, 2025

Introduction

ALIMTA (pemetrexed) stands as a cornerstone in the treatment of non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM). Since its FDA approval in 2004, ALIMTA has expanded its role in oncological regimens, driven by evolving clinical evidence, strategic marketing, and broader shifts in oncology pharmacotherapy. This comprehensive analysis examines its market dynamics, regulatory landscape, competitive environment, and financial trajectory, offering a detailed view of its position within the global oncology landscape.

---

Pharmacological Profile and Clinical Utility

ALIMTA is a folate analog metabolic inhibitor targeting thymidylate synthase, disrupting DNA synthesis in rapidly dividing cancer cells. Its clinical efficacy in combination therapies, notably with cisplatin for NSCLC and with cisplatin and doxorubicin for mesothelioma, underpins its widespread adoption. The drug’s well-characterized safety profile and approval across multiple regions have cemented its utility in first-line and subsequent treatment settings.

---

Market Dynamics

1. Growing Incidence of Target Cancers

The rising prevalence of NSCLC and mesothelioma globally underpins ALIMTA’s sustained demand. According to global cancer statistics, lung cancer remains the leading cause of cancer-related mortality, with an estimated 2.2 million new cases in 2020 [1]. Mesothelioma, although rarer, sees increasing incidence correlating with industrial exposure, notably asbestos, which remains a public health concern in many regions [2].

2. Expansion of Indications and Line of Therapy

Initially approved for mesothelioma and later for nonsquamous NSCLC, ALIMTA’s label has expanded through clinical trials demonstrating efficacy in combination with immunotherapy agents and other chemotherapeutics. The integration of immune checkpoint inhibitors like pembrolizumab with ALIMTA has opened new therapeutic corridors, particularly in first-line NSCLC, propelling sales growth.

3. Advancements in Combination Regimens

The shift toward personalized medicine in oncology has led to combinations of ALIMTA with targeted therapies and immunotherapies, improving outcomes and extending its market lifespan. Notably, trials combining ALIMTA with pembrolizumab have demonstrated encouraging response rates, prompting regulatory reviews and potential label updates, which are poised to expand its utility.

4. Competitive Landscape

ALIMTA faces competition from emerging agents, including immune checkpoint inhibitors and newer chemotherapeutics such as docetaxel and nab-paclitaxel. While these agents challenge ALIMTA’s dominance in certain indications, its established clinical efficacy and favorable safety profile sustain its market share, especially in regions where access to newer therapies remains limited.

5. Regulatory and Reimbursement Environment

Global regulatory authorities continue approving ALIMTA for additional indications or in combination therapies, bolstering its market presence. However, pricing pressures, especially in price-sensitive markets like India and emerging economies, influence reimbursement strategies, impacting sales volume and profit margins.

---

Financial Trajectory

1. Revenue Trends and Market Share

Pfizer’s legacy as the primary manufacturer of ALIMTA ensures it maintains a significant revenue stream. In 2021, ALIMTA generated approximately $1.46 billion worldwide, representing a decline from peak sales near $1.86 billion in 2018, attributable to generic competition and market saturation [3]. Nonetheless, recent indications, such as its incorporation into combination regimens for NSCLC, have stabilized revenues.

2. Patent and Market Exclusivity

ALIMTA's primary patent protections expired in key markets by 2020, leading to increased generic entries. Despite this, Pfizer’s strategic marketing, co-formulation efforts, and potential new indications mitigate erosion of revenues. Patent challenges and the possibility of biosimilar development pose ongoing threats.

3. Impact of Biosimilars and Generics

The introduction of biosimilars and generic pemetrexed formulations in the U.S. and Europe has exerted downward pressure on prices—reducing margins but expanding access. As of 2022, generic versions constitute a significant share of the PEM market in numerous countries, compressing revenue per unit but potentially increasing overall volume.

4. Future Revenue Streams

Prospective growth hinges on several factors:

• New Indications: Trials exploring ALIMTA in combination with immunotherapies for additional cancers like gastrointestinal malignancies may unlock new markets.

• Population Expansion: Aging populations in developed countries and rising cancer prevalence are driving increased utilization.

• Regional Penetration: Growth in Asia-Pacific and Latin America offers untapped markets, especially with tiered pricing and reimbursement strategies.

5. R&D and Pipeline Developments

Pfizer’s ongoing research into next-generation antifolates and combination therapies may influence ALIMTA’s long-term financial trajectory. While no novel formulations are currently imminent, incremental improvements and companion diagnostic developments pose opportunities.

---

Strategic Considerations

Market Entry Barriers and Opportunities

While generic competition limits premium pricing, Pfizer’s focus on generating adjunct revenue via labeling extensions and combination therapies creates growth avenues. Collaborations with biotech firms exploring immune-oncology combinations further diversify potential revenue sources.

Geographic Expansion Strategies

Customized pricing and regulatory negotiations in emerging markets are critical for expanding ALIMTA’s footprint. Strategic partnerships and licensing arrangements could foster broader access, balancing volume increases against lower unit revenues.

Patent and Intellectual Property Strategy

Preserving orphan and formulation patents in select markets provides short- to mid-term market exclusivity. Engagement in patent litigation and defending against biosimilar challenges remain pivotal to revenue retention.

---

Conclusion: Financial Outlook and Market Stability

ALIMTA remains a vital component of oncology treatment pathways, with its financial trajectory influenced by patent expirations, competitive pressures, and innovative combination therapies. While revenue growth faces headwinds from biosimilar entry, strategic expansion into novel indications, regional growth, and combination regimens underpin its sustained market relevance. The next phase for ALIMTA hinges on clinical innovation, regulatory adaptations, and global access strategies.

---

Key Takeaways

• Stable Demand Amidst Competition: ALIMTA's established efficacy ensures continued demand, particularly in combination with emerging immunotherapies.
• Revenue Compression from Generics: Patent expirations and biosimilar entries have led to price erosion, though diversification into new indications mitigates long-term decline.
• Growth Opportunities in Emerging Markets: Tailored market access and regional expansion can offset mature market saturation.
• Innovation-Driven Growth: Ongoing clinical trials exploring ALIMTA in combination therapies could expand its therapeutic landscape.
• Strategic Patent Management: Active defense of key patents will remain crucial for maintaining exclusivity and revenue streams.

---

FAQs

1. How has patent expiration affected ALIMTA’s market revenues?
Patent expirations in major markets have introduced generic pemetrexed, causing significant price reductions and compressing Pfizer’s profit margins. However, strategic label extensions and combination therapies provide revenue buffers.

2. What are the competitive threats facing ALIMTA?
Emerging immune checkpoint inhibitors, targeted therapies, and biosimilars pose competitive threats, especially as they begin to demonstrate comparable efficacy in certain indications.

3. Are there upcoming regulatory approvals that could impact ALIMTA’s market?
Yes. Clinical trials investigating ALIMTA with immunotherapies are under regulatory review, which could lead to additional indications and boost sales if approved.

4. Which regional markets offer the greatest growth potential for ALIMTA?
Asia-Pacific and Latin America are primary targets, owing to increasing cancer rates, expanding healthcare infrastructure, and a growing acceptance of cancer combination therapies.

5. How has the integration of immunotherapy impacted ALIMTA’s financial prospects?
Combining ALIMTA with immune checkpoint inhibitors like pembrolizumab has demonstrated promising efficacy, positioning it as a cornerstone in combination regimens and supporting its future revenue opportunities.

---

Sources

[1] Globocan 2020: Estimated Cancer Incidence and Mortality. International Agency for Research on Cancer.
[2] Robinson, B. W., et al. (2016). "Malignant pleural mesothelioma: Advances in pathogenesis, diagnosis, and therapy." CA: A Cancer Journal for Clinicians.
[3] Pfizer Annual Reports (2018-2021).